Analysts Set Outset Medical, Inc. (NASDAQ:OM) Target Price at $10.00

Outset Medical, Inc. (NASDAQ:OM) has received an average recommendation of “Moderate Buy” from the five ratings firms that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, two have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $10.00.

OM has been the subject of several research analyst reports. Royal Bank Of Canada reissued a “sector perform” rating and set a $7.00 price objective on shares of Outset Medical in a research note on Wednesday, December 17th. Stifel Nicolaus dropped their price target on Outset Medical from $14.00 to $8.00 and set a “buy” rating for the company in a research report on Wednesday, January 7th. Weiss Ratings restated a “sell (e+)” rating on shares of Outset Medical in a research report on Monday, December 29th. BTIG Research lowered their target price on shares of Outset Medical from $17.00 to $15.00 and set a “buy” rating on the stock in a research note on Thursday, February 12th. Finally, Wall Street Zen cut shares of Outset Medical from a “hold” rating to a “sell” rating in a research note on Sunday, February 8th.

Insider Activity at Outset Medical

In other Outset Medical news, CEO Leslie Trigg sold 11,794 shares of the stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $5.12, for a total transaction of $60,385.28. Following the transaction, the chief executive officer directly owned 107,823 shares in the company, valued at $552,053.76. This trade represents a 9.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, General Counsel John L. Brottem sold 9,314 shares of Outset Medical stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $5.12, for a total transaction of $47,687.68. Following the completion of the transaction, the general counsel owned 36,957 shares in the company, valued at approximately $189,219.84. The trade was a 20.13% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 42,458 shares of company stock valued at $199,805 over the last 90 days. 2.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Los Angeles Capital Management LLC bought a new stake in shares of Outset Medical in the 4th quarter valued at about $29,000. Legal & General Group Plc purchased a new position in Outset Medical in the 2nd quarter worth approximately $34,000. Ameritas Investment Partners Inc. bought a new stake in Outset Medical in the second quarter valued at approximately $35,000. BNP Paribas Financial Markets boosted its stake in shares of Outset Medical by 7,013.8% during the second quarter. BNP Paribas Financial Markets now owns 2,063 shares of the company’s stock valued at $40,000 after purchasing an additional 2,034 shares during the period. Finally, HRT Financial LP purchased a new stake in shares of Outset Medical during the fourth quarter valued at approximately $58,000.

Outset Medical Stock Performance

NASDAQ OM opened at $3.53 on Thursday. The company’s 50 day simple moving average is $4.33 and its two-hundred day simple moving average is $8.95. The company has a debt-to-equity ratio of 0.76, a current ratio of 6.67 and a quick ratio of 5.77. Outset Medical has a 1 year low of $3.10 and a 1 year high of $21.98. The stock has a market capitalization of $64.63 million, a PE ratio of -0.52 and a beta of 2.08.

About Outset Medical

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.